The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma

References

• Bataille R, Manolagas SC, Berenson JR. Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1997;11:349–361.
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–3420.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Bergui L, Gregoretti MG, et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991;77:2688–2693.
   PubMed Web of Science ®Google Scholar
• Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005;45:872–877.
   PubMed Web of Science ®Google Scholar
• Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000;95:1056–1065.
   PubMed Web of Science ®Google Scholar
• Pilarski LM, Seeberger K, Coupland RW, et al. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol 2002;30:221–228.
   PubMed Web of Science ®Google Scholar
• Reiman T, Seeberger K, Taylor BJ, et al. Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood 2001;98:2791–2799.
   PubMed Web of Science ®Google Scholar
• Pilarski LM, Baigorri E, Mant MJ, et al. Multiple myeloma includes phenotypically defined subsets of clonotypic CD20+ B cells that persist during treatment with rituximab. Clin Med Oncol 2008;2:275–287.
   PubMedGoogle Scholar
• Kirshner J, Thulien KJ, Martin LD, et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 2008;112:2935–2945.
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff MH, Aggeler J, Ram TG, Bissell MJ. Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development 1989;105:223–235.
   PubMed Web of Science ®Google Scholar
• Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999;93:3044–3052.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 2004;32:685–691.
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431–436.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006;42:1564–1573.
   PubMed Web of Science ®Google Scholar
• Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005;105:4163–4169.
   PubMed Web of Science ®Google Scholar
• Knight DW. Feverfew: chemistry and biological activity. Nat Prod Rep 1995;12:271–276.
   PubMed Web of Science ®Google Scholar
• Ross JJ, Arnason JT, Birnboim HC. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med 1999;65:126–129.
   PubMed Web of Science ®Google Scholar
• Wiedhopf RM, Young M, Bianchi E, Cole JR. Tumor inhibitory agent from Magnolia grandiflora (Magnoliaceae). I. Parthenolide. J Pharm Sci 1973;62:345.
   PubMed Web of Science ®Google Scholar
• Woynarowski JM, Konopa J. Inhibition of DNA biosynthesis in HeLa cells by cytotoxic and antitumor sesquiterpene lactones. Mol Pharmacol 1981;19:97–102.
   PubMed Web of Science ®Google Scholar
• Zhang S, Ong CN, Shen HM. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 2004;208:143–153.
   PubMed Web of Science ®Google Scholar
• Nakshatri H, Rice SE, Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 2004;23:7330–7344.
   PubMed Web of Science ®Google Scholar
• deGraffenried LA, Chandrasekar B, Friedrichs WE, et al. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 2004;15: 885–890.
   PubMed Web of Science ®Google Scholar
• Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17–26.
   PubMed Web of Science ®Google Scholar
• Suvannasankha A, Crean CD, Shanmugam R, et al. Antimyeloma effects of a sesquiterpene lactone parthenolide. Clin Cancer Res 2008;14:1814–1822.
   PubMed Web of Science ®Google Scholar
• Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007;110:4427–4435.
   PubMed Web of Science ®Google Scholar
• Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. Aminoparthenolides as novel anti-leukemic agents: discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett 2009;19:4346–4349.
   PubMed Web of Science ®Google Scholar
• Curry EA 3rd, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 2004; 22:299–305.
   PubMed Web of Science ®Google Scholar
• Nasim S, Crooks PA. Antileukemic activity of aminoparthenolide analogs. Bioorg Med Chem Lett 2008;18:3870–3873.
   PubMed Web of Science ®Google Scholar
• Hassane DC, Guzman ML, Corbett C, et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008;111:5654–5662.
   PubMed Web of Science ®Google Scholar
• Steele AJ, Jones DT, Ganeshaguru K, et al. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. Leukemia 2006;20:1073–1079.
   PubMed Web of Science ®Google Scholar
• Schmidt TJ. Helenanolide-type sesquiterpene lactones–III. Rates and stereochemistry in the reaction of helenalin and related helenanolides with sulfhydryl containing biomolecules. Bioorg Med Chem 1997;5(4) 107: 645–653.
   Web of Science ®Google Scholar
• Nanduri S, Nyavanandi VK, Thunuguntla SS, et al. Synthesis and structure-activity relationships of andrographolide analogues as novel cytotoxic agents. Bioorg Med Chem Lett 2004;14:4711–4717.
   PubMed Web of Science ®Google Scholar
• Hidalgo MA, Romero A, Figueroa J, et al. Andrographolide interferes with binding of nuclear factor-kappaB to DNA in HL-60-derived neutrophilic cells. Br J Pharmacol 2005;144: 680–686.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chan GK, Li J, Fong WF, Cheung HY. Molecular interaction between andrographolide and glutathione follows second order kinetics. Chem Pharm Bull (Tokyo) 2008;56: 1229–1233.
   PubMed Web of Science ®Google Scholar
• Xia YF, Ye BQ, Li YD, et al. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol 2004;173:4207–4217.
   PubMed Web of Science ®Google Scholar
• Puri A, Saxena R, Saxena RP, Saxena KC, Srivastava V, Tandon JS. Immunostimulant agents from Andrographis paniculata. J Nat Prod 1993;56:995–999.
   PubMed Web of Science ®Google Scholar
• Choudhury BR, Haque SJ, Poddar MK. In vivo and in vitro effects of kalmegh (Andrographis paniculata) extract and andrographolide on hepatic microsomal drug metabolizing enzymes. Planta Med 1987;53:135–140.
   PubMedGoogle Scholar
• Matsuda T, Kuroyanagi M, Sugiyama S, Umehara K, Ueno A, Nishi K. Cell differentiation-inducing diterpenes from Andrographis paniculata Nees. Chem Pharm Bull (Tokyo) 1994;42:1216–1225.
   PubMed Web of Science ®Google Scholar
• Manikam SD, Stanslas J. Andrographolide inhibits growth of acute promyelocytic leukaemia cells by inducing retinoic acid receptor-independent cell differentiation and apoptosis. J Pharm Pharmacol 2009;61:69–78.
   PubMed Web of Science ®Google Scholar
• Han C, Barrios FJ, Riofski MV, Colby DA. Semisynthetic derivatives of sesquiterpene lactones by palladium-catalyzed arylation of the alpha-methylene-gamma-lactone substructure. J Org Chem 2009;74:7176–7179.
   PubMed Web of Science ®Google Scholar
• Dalton WS, Hazlehurst L, Shain K, Landowski T, Alsina M. Targeting the bone marrow microenvironment in hematologic malignancies. Semin Hematol 2004;41(Suppl. 4):1–5.
   PubMed Web of Science ®Google Scholar
• Tancred TM, Belch AR, Reiman T, Pilarski LM, Kirshner J. Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J Histochem Cytochem 2009;57:239–247.
   PubMed Web of Science ®Google Scholar
• Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 2001;8:759–766.
   PubMed Web of Science ®Google Scholar
• Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332–2336.
   PubMed Web of Science ®Google Scholar
• Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190–197.
   PubMed Web of Science ®Google Scholar
• Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 2002;16:1182–1188.
   PubMed Web of Science ®Google Scholar
• Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645–659.
   PubMed Web of Science ®Google Scholar
• Hazlehurst LA, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 2001;20:43–50.
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175–1182.
   PubMed Web of Science ®Google Scholar
• Perez LE, Parquet N, Shain K, et al. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol 2008;180:1545–1555.
   PubMed Web of Science ®Google Scholar